BR112012019666A2 - estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística - Google Patents

estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística

Info

Publication number
BR112012019666A2
BR112012019666A2 BR112012019666A BR112012019666A BR112012019666A2 BR 112012019666 A2 BR112012019666 A2 BR 112012019666A2 BR 112012019666 A BR112012019666 A BR 112012019666A BR 112012019666 A BR112012019666 A BR 112012019666A BR 112012019666 A2 BR112012019666 A2 BR 112012019666A2
Authority
BR
Brazil
Prior art keywords
sgc
treatment
combination
cystic fibrosis
enhancers
Prior art date
Application number
BR112012019666A
Other languages
English (en)
Inventor
Von Degenfeld Georges
Peter Stasch Johannes
Sandner Peter
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012019666(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112012019666A2 publication Critical patent/BR112012019666A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)

Abstract

estimuladores da sgc ou atividores da sgc individualmente e em combinação combinação com inibidores da pde5 para o tratamento de fibrose cística. a presente inveção refere-se a guanilato ciclase solúvel (sgc) e fosfodiesterases (pdes) e à farmacologia de estimuladores da sgc, ativadores da sgc einibidores da pde. mais particulamente, a invenção se refere ao uso de estimuladores da sgc and ativadores da sgc em combinação com inibidores da pde5 para a preparação de medicamentos para o tratamento de fibrose cística (cf).
BR112012019666A 2010-02-05 2011-02-03 estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística BR112012019666A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10152727 2010-02-05
PCT/EP2011/051532 WO2011095534A1 (en) 2010-02-05 2011-02-03 sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS

Publications (1)

Publication Number Publication Date
BR112012019666A2 true BR112012019666A2 (pt) 2017-06-20

Family

ID=43759663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019666A BR112012019666A2 (pt) 2010-02-05 2011-02-03 estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística

Country Status (32)

Country Link
US (1) US20130035340A1 (pt)
EP (1) EP2531187B1 (pt)
JP (2) JP6143461B2 (pt)
KR (1) KR101793304B1 (pt)
CN (3) CN104800219A (pt)
AU (1) AU2011212521B2 (pt)
BR (1) BR112012019666A2 (pt)
CA (1) CA2788969C (pt)
CL (1) CL2012002173A1 (pt)
CR (1) CR20120408A (pt)
CY (1) CY1116878T1 (pt)
DK (1) DK2531187T3 (pt)
EA (1) EA025177B1 (pt)
ES (1) ES2548394T3 (pt)
HK (1) HK1212892A1 (pt)
HR (1) HRP20151187T1 (pt)
HU (1) HUE028008T2 (pt)
IL (1) IL221012B (pt)
MA (1) MA33984B1 (pt)
MX (1) MX342944B (pt)
MY (2) MY159697A (pt)
NZ (1) NZ601612A (pt)
PL (1) PL2531187T3 (pt)
PT (1) PT2531187E (pt)
RS (1) RS54336B1 (pt)
SG (1) SG182819A1 (pt)
SI (1) SI2531187T1 (pt)
SM (1) SMT201500286B (pt)
TN (1) TN2012000397A1 (pt)
UA (1) UA112962C2 (pt)
WO (1) WO2011095534A1 (pt)
ZA (1) ZA201205532B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601612A (en) * 2010-02-05 2014-08-29 Bayer Ip Gmbh Sgc stimulators or sgc activators alone and in combination with pde5 inhibitors for the treatment of cystic fibrosis
HUE025162T2 (en) 2010-05-26 2016-04-28 Adverio Pharma Gmbh Use of sGC stimulators, sGC activators alone or in combination with PDE5 inhibitors to treat systemic sclerosis (SSc).
US20130158028A1 (en) * 2010-06-25 2013-06-20 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
CN104619695B (zh) 2012-09-07 2018-04-10 勃林格殷格翰国际有限公司 作为可溶性鸟苷酸环化酶活化剂的烷氧吡唑
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN106304835A (zh) 2013-12-11 2017-01-04 铁木医药有限公司 sGC刺激剂
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
AU2015292833B2 (en) 2014-07-22 2019-11-28 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
MX2017003518A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2016044447A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
CA3008776A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
EP3554506B1 (en) 2016-12-16 2021-04-28 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as cftr potentiators
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
KR100720844B1 (ko) * 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
AU2008250643A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC stimulators, sGC activators and combinations for the treatment of urological disorders
EA201070339A1 (ru) 2007-09-06 2010-10-29 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
TW200938529A (en) 2007-12-03 2009-09-16 Smithkline Beecham Corp Compounds
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
EP2296685B1 (en) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
NZ601612A (en) * 2010-02-05 2014-08-29 Bayer Ip Gmbh Sgc stimulators or sgc activators alone and in combination with pde5 inhibitors for the treatment of cystic fibrosis

Also Published As

Publication number Publication date
JP6143461B2 (ja) 2017-06-07
WO2011095534A1 (en) 2011-08-11
IL221012A0 (en) 2012-09-24
JP2016155857A (ja) 2016-09-01
AU2011212521B2 (en) 2015-11-19
HUE028008T2 (en) 2016-11-28
MX2012009011A (es) 2012-09-07
CA2788969C (en) 2017-11-21
MA33984B1 (fr) 2013-02-01
EA201290702A1 (ru) 2013-02-28
CL2012002173A1 (es) 2013-05-17
KR101793304B1 (ko) 2017-11-02
ZA201205532B (en) 2014-12-23
CN104800219A (zh) 2015-07-29
CY1116878T1 (el) 2017-04-05
PT2531187E (pt) 2015-10-20
AU2011212521A1 (en) 2012-08-16
MY160856A (en) 2017-03-31
UA112962C2 (uk) 2016-11-25
TN2012000397A1 (en) 2014-01-30
PL2531187T3 (pl) 2016-01-29
HK1212892A1 (zh) 2016-06-24
EA025177B1 (ru) 2016-11-30
KR20120125276A (ko) 2012-11-14
MX342944B (es) 2016-10-18
SI2531187T1 (sl) 2016-01-29
DK2531187T3 (en) 2015-11-09
EP2531187A1 (en) 2012-12-12
IL221012B (en) 2018-01-31
CA2788969A1 (en) 2011-08-11
CR20120408A (es) 2013-02-12
US20130035340A1 (en) 2013-02-07
CN102770133A (zh) 2012-11-07
JP2013518851A (ja) 2013-05-23
ES2548394T3 (es) 2015-10-16
NZ601612A (en) 2014-08-29
JP6270907B2 (ja) 2018-01-31
EP2531187B1 (en) 2015-08-12
HRP20151187T1 (hr) 2015-12-04
MY159697A (en) 2017-01-13
CN107929271A (zh) 2018-04-20
RS54336B1 (en) 2016-02-29
SG182819A1 (en) 2012-09-27
SMT201500286B (it) 2016-01-08

Similar Documents

Publication Publication Date Title
BR112012019666A2 (pt) estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística
MY169072A (en) Solid dispersions of a erb2 (her2) inhibitor
WO2011086531A3 (en) New anti-malarial agents
WO2010081647A3 (en) Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
BRPI1011838B8 (pt) compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk
CR20120427A (es) Derivados de pirazol como inhibidores de jak
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
MX2009009597A (es) Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
UY32203A (es) Amino pirimidinas y su uso en terapia
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
UA116875C2 (uk) Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
MX2014003025A (es) Compuestos de triazolopiridina como inhibidores de fosfodiesterasa 10a.
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
BR112014017481A8 (pt) formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
WO2012145575A3 (en) Therapy for leukemia
UY31839A (es) Compuestos
BR112014020212A8 (pt) aminopirazina, formulação farmacêutica, processo para a preparação de um derivado de aminopirazina, e, intermediário.
MX343598B (es) Teobromina en combinacion con un expectorante o un mucolitico para uso en terapia.
CR11869A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
IN2014DN10134A (pt)
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ADVERIO PHARMA GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]